EARLY

Available as early as ten weeks of pregnancy.

RELIABLE

The test qualifies for the strict requirements of ISO, CE-IVD, and EMQN.

INNOVATIVE

Focus Plus technology increases the reliability of the test compared to a regular NIPT test.
baby and mom_303060878
image-layers-3-02
image-layers-3-03
image-layers-3-04
image-layers-3-05
image-layers-3-06

SAFE

A maternal blood sample is required for fetal DNA testing.

COMPREHENSIVE

NIPTIFY covers all the essential fetal chromosomal diseases, including microdeletions.

SECURE

NIPTIFY laboratory stores your genomic data according to strict regulations.

What does NIPTIFY provides?

disainielemendid-10

Five most common chromosomal diseases

  1. Down syndrome
  2. DiGeorge syndrome (microdeletion)
  3. Edwards syndrome
  4. Turner syndrome
  5. Patau syndrome
disainielemendid-07

Seven clinically relevant microdeletions

disainielemendid-05

A large set of other conditions

NIPTIFY performs whole genome analysis and reports all clinically relevant trisomy or monosomy cases as incidental findings. For example:
disainielemendid-02

Fetal sex

NIPTIFY determines the chromosomal sex of the fetus with 100% accuracy. 
disainielemendid-06

Choose the most suitable clinic for you to make an appointment with your obstetrician or midwife and perform the NIPTIFY test.

Why should you choose NIPTIFY for microdeletion detection?

The combined first-trimester screening test is unable to detect microdeletions. A DNA-based NIPT can only assess the risk of microdeletions already at the early phase of pregnancy. NIPTIFY Focus Plus test monitors DiGeorge’s syndrome and seven additional microdeletions risks.
DiGeorge’s syndrome (22q11) is a commonly occurring condition (1:1100 – 1:1500) that causes congenital heart abnormalities and mental retardation. This microdeletion develops spontaneously (de novo) and does not correlate with maternal age. Therefore, NIPTIFY testing is for all families to screen for the risk of the disease.

Why should you choose NIPTIFY for microdeletion detection?

The combined first-trimester screening test is unable to detect microdeletions. A DNA-based NIPT can only assess the risk of microdeletions already at the early phase of pregnancy. NIPTIFY Focus Plus test monitors DiGeorge’s syndrome and seven additional microdeletions risks.
DiGeorge’s syndrome (22q11) is a commonly occurring condition (1:1100 – 1:1500) that causes congenital heart abnormalities and mental retardation. This microdeletion develops spontaneously (de novo) and does not correlate with maternal age. Therefore, NIPTIFY testing is for all families to screen for the risk of the disease.
disainielemendid-09

NIPTIFY is a CE-IVD-validated and registered in vitro medical diagnostic device. The test can be distributed all over European Union.

disainielemendid-08

The NIPTIFY medical laboratory has ISO 15189:2012 accreditation and follows the highest standards.

disainielemendid-13-v2

NIPTIFY participates in the EMQN quality assurance test and has consistently earned the highest possible scores.

TECHNOLOGY

NIPTIFY uses the modern Focus Plus DNA sequencing technology, which enriches fetal DNA. As a result, NIPTIFY analysis 3.6 times more fetal origin DNA than a regular NIPT test, increasing the accuracy and sensitivity.

Focus Plus technology is designed for routine and reliable screening purposes. The need for re-testing is close to zero, and the test is suitable for overweight patients.

#zikzag_carousel_63d68c5f8e9f2 .slick-arrow:before, #zikzag_carousel_63d68c5f8e9f2 .slick-arrow:after { border-color: #222222; } #zikzag_carousel_63d68c5f8e9f2 .slick-arrow{ background-color: #222222; }#zikzag_carousel_63d68c5f8e9f2 .slick-arrow:hover { background-color: #989898; } #zikzag_carousel_63d68c5f8e9f2 .slick-arrow:hover:after, #zikzag_carousel_63d68c5f8e9f2 .slick-arrow:hover:before { border-color: #989898; }